Skip to content

Study · Animal study (in vivo) · mouse · 2017

1 result

AMPK contributes to aerobic exercise-induced antinociception downstream of endocannabinoids.

King-Himmelreich TS, Möser CV, Wolters MC, Schmetzer J, Schreiber Y, Ferreirós N, Russe OQ, Geisslinger G, Niederberger E

Neuropharmacology4 May 2017Cited by 19 (Europe PMC)

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study1

1 result from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In wild-type mice, adding AICAR to AM251 restored exercise-induced antinociception that AM251 reversed.

    In plain wordsIn mice, adding AICAR restored exercise-related pain reduction compared with AM251 alone.

    Outcome
    DecreaseInflammatory nociception
    Study

    mousen: not reported in source

    wild-type mice undergoing treadmill running and formalin challenge
    Comparator
    AM251 before treadmill running
    Outcome group
    Pain · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    However, if mice received AM251 in combination with the AMPK activator 5-amino-1-β-d-ribofuranosyl-imidazole-4-carboxamide (AICAR), the positive effect of treadmill running on inflammatory nociception was restored, indicating that AMPK affects exercise-induced antinociception downstream of endocannabinoids.
    2 context sentences
    Summary · context
    Accordingly, treatment of wild type mice with the CB1 inverse agonist AM251 prior to the treadmill running reversed exercise-induced antinociception.
    Summary · context
    In this study, we investigated exercise-induced effects after a single bout of treadmill running on the mouse model of formalin-induced inflammatory nociception.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    21 Oct 2026, 15:58 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 12:50 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.